1. GlaxoSmithKline Local Label. *

2. Honein MA, Paulozzi LJ, Cragan JD, et al. Evaluation of selected characteristics of pregnancy drug registries. Teratology 1999;60:356-364.*

3. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499-507.*

4. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88:159-170 (Study WEUSRTP2280).*

5. O'Brien L, Einarson TR, Sarkar M, Einarson A, Koren G. Does paroxetine cause cardiac malformations?. JOGC 2008;30(8):696-01.*

6. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007;29:918-926.*

7. Data on File. Study EPIP083, December 2005. *

8. Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester of pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16(10):1075-1085. EPI40404.*

9. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with the use of paroxetine during pregnancy. Am J Psychiatry 2008;165:749-752.*

10. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007;16(10):1086-1094.*

11. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569 doi:10.1136/bmj.b3569.*

12. Kornum JB, Nielsen RB, Pedersen L, et al. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010;2:29-36.*

13. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. NEJM 2007;356(26):2675-2683. Study WWE113655.*

14. Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Research (Part B) 2007;80:18-27.*

15. Berard A, Sheehy O. Paroxetine use during pregnancy and adverse pregnancy outcomes in the absence of detection bias. European Psychiatry 2010;25(Suppl 1):1687(abstract).*

16. Bakker MK, Kerstjens-Frederikse WS, Buys CHCM, et al. First trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010;88:94-100.*

17. Kallen B. Letter to the editor: Antidepressant drugs during pregnancy and infant congenital heart defects. Reproductive Toxicology 2006;21:221-222.*

18. Kallen BAJ, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Research (Part A) 2007;79:301-308.*

19. Ericson A, Kallen B, Wilholm BE. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503-508.*

20. Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 2005;25:59-73.*

21. Reis M and Källén B. Delivery outcomes after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-1733.*

22. Malm H, Klaukka, T, and Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106:1289-1296.*

23. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66(5):695-705.*

24. Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009;84(1):23-27.*

25. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Colvin L, Slack-Smith L, Stanley FJ, et al. Birth Defects Research (Part A) 2011;91:142-152.*

26. Kulin NA, Pastusz-ak A, Sage S, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors - A prospective controlled multicenter study. JAMA 1998;279:609-610.*

27. Maschi S, Clavenna A, Campi R, et al. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 2008;115:283-289.*

28. Simon GE, Cunninghan ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002;159:2055-2061.*

29. Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003;188:812-815.*

30. Merlob P, Birk E, Sirota L, et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 2009;85:837-841.*

31. Hostetter A, Stowe ZN, Strader JR, et al. Dose of selective serotonin uptake inhibitors across pregnancy: Clinical implications. Depress Anxiety 2000;11:51-57.*

32. Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. NEJM 2007;356(26):2684-2692.*

33. Inman W, Kubota K, Pearce G, et al. Prescription-event monitoring (PEM) report number 6.Paroxetine. Pharmacoepidemiol Drug Saf 1993;2:393-422.*

34. Mackay FJ, Dunn NR, Wilton LV, et al. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 1997;6:235-246.*

35. Wilton LV, Pearce GL, Martin RM, et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998;105:882-889.*

36. Data on File. RM2006/00744/00, 2000. *

37. Nakhai-Pour HR, Broy P, Bérard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 2010;182:1031-1037.*

38. Broy P, Berard A. Gestational exposure to antidepressants and the risk of spontaneous abortion: a review. Current Drug Delivery 2010;7:76-92.*

39. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003;142:402-8.*

40. Misri S, Reebye P, Kendrick K, et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 2006;163:1026-1032.*

41. Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007;161:22-29.*

42. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010;125:e600-e608. DOI:10.1542/peds.2008-3655.*

43. Costei, AE, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;153:1129-1132.*

44. Costei AE, Ho T, Kozer E, et al. Perinatal outcome following third trimester exposure to paroxetine [abstract]. In: American Pediatric Society for Pediatric Research Annual Meeting. Baltimore, MD, May 4-7, 2002, Abstract No.387 *

45. Pearson KH, Nonacs RM, Viguera AC, et al. Birth outcomes following prenatal exposure to antidepressants. J Clin Psychiatry 2007;68(8):1284-1289.*

46. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368-375.*

47. Oberlander TF, Grunau RE, Fitzgerald C. Pain reactivity in 2 month old infants after prenatal and postnatal selective serotonin reuptake inhibitor medication exposure. Pediatrics 2006;115:411-425.*

48. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63:898-906.*

49. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312-316.*

50. Dubnov-Raz G, Juurlink DN, Fogelman R, et al. Anenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics 2008;122Le710-e715.*

51. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-587.*

52. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety 2009;18:246-252.*

53. Calderon-Margalit R, Qiu C, Ornoy A, et al. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol 2009;201:579.e1-8.*

54. Sanz EJ, De-las-Cuevas C, Kiuri A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatoal withdrawal syndrome: a database analysis. Lancet 2005;365:482-487.*

55. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173-176.*